XML 42 R32.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Oct. 31, 2015
Oct. 31, 2014
Oct. 31, 2015
Oct. 31, 2014
Net revenue $ 2,971 $ 1,882 $ 5,793 $ 3,793
Sales and marketing costs (834) (1,203) (1,863) (2,246)
Stock- based compensation expense (748) (820) (1,523) (1,627)
Personalized Oncology Solutions [Member]        
Net revenue 486 452 971 792
Direct cost of services (567) (745) (1,202) (1,498)
Sales and marketing costs (189) (423) (521) (877)
Other operating expenses 0 0 0 0
Stock- based compensation expense [1] 0 0 0 0
Segment profit (loss) (270) (716) (752) (1,583)
Translational Oncology Solutions [Member]        
Net revenue 2,485 1,430 4,822 3,001
Direct cost of services (1,441) (943) (3,030) (1,905)
Sales and marketing costs (620) (611) (1,197) (1,036)
Other operating expenses (873) (1,142) (1,806) (2,460)
Stock- based compensation expense [1] 0 0 0 0
Segment profit (loss) (450) (1,266) (1,211) (2,400)
Unallocated Corporate Overhead [Member]        
Net revenue 0 0 0 0
Direct cost of services 0 0 0 0
Sales and marketing costs 0 0 0 0
Other operating expenses (1,026) (864) (1,904) (1,777)
Stock- based compensation expense [1] (748) (820) (1,523) (1,627)
Segment profit (loss) (1,774) (1,684) (5,427) (3,404)
Consolidated [Member]        
Net revenue 2,971 1,882 5,793 3,793
Direct cost of services (2,008) (1,688) (4,232) (3,403)
Sales and marketing costs (809) (1,034) (1,718) (1,913)
Other operating expenses (1,899) (2,006) (3,710) (4,237)
Stock- based compensation expense [1] (748) (820) (1,523) (1,627)
Segment profit (loss) $ (2,493) $ (3,666) $ (5,390) $ (7,387)
[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.